key: cord-0853183-nakss8ag
authors: Palermo, Nadine E; Sadhu, Archana R; McDonnell, Marie E
title: Diabetic Ketoacidosis in COVID-19: unique concerns and considerations
date: 2020-06-18
journal: J Clin Endocrinol Metab
DOI: 10.1210/clinem/dgaa360
sha: 67c4ad2810c089ce663a5090b5aad3e9b209682a
doc_id: 853183
cord_uid: nakss8ag

While individuals with diabetes appear to be at similar risk for SARS-CoV-2 infection than those without diabetes, they are more likely to suffer severe consequences, including death. Diabetic ketoacidosis (DKA) is a common and potentially lethal acute complication of diabetes arising from a relative insulin deficiency, which occurs more often in those with type 1 diabetes and in the setting of moderate to severe illness. Early reports indicate that among patients with preexisting diabetes, DKA may be a common complication of severe COVID-19 and a poor prognostic sign. This clinical perspective explores the key elements of caring for individuals with DKA during the COVID-19 pandemic through two cases. Topics addressed include diagnosis, triage, and the fundamental principles of treatment with a focus on the importance of characterizing DKA severity and medical complexity to determine the best approach. As discussed, some tenets of DKA management may require flexibility in the setting of COVID-19 due to important public health goals such as preventing transmission to highest risk individuals, reducing health care worker exposure to infected patients and preserving personal protective equipment (PPE). Evidence for alternative treatment strategies is explored with special attention placed on treatment options that may be more relevant during the pandemic including use of subcutaneous insulin therapy. Finally, DKA is often a preventable condition. We include evidence-based strategies and guidance designed to empower clinicians and patients to avoid this serious complication when possible.

A c c e p t e d M a n u s c r i p t Along these lines, clinicians have reconsidered alternative methods for management of hyperglycemic crisis to achieve the triple goal of protecting patients with diabetes from SARS-CoV-2 exposure, reducing exposure to health care personnel during the care of COVID-19 patients, and limiting use of the intensive care unit (ICU) beds for non-COVID-19

care. Such methods include identifying patients who may be able to be treated outside of the hospital or for a short period in the ED. In addition, the role of subcutaneous insulin for management of mild to moderate DKA has resurfaced as not only an evidenced-based alternative to IVI requiring less frequent glucose monitoring, but as a critical tool to employ during the pandemic to reduce time required at the bedside managing insulin.

The purpose of this communication is to provide guidance for clinicians who care for patients at risk for DKA and patients who develop DKA in the setting of SARS-CoV-2 A c c e p t e d M a n u s c r i p t 7 infection. The discussion also addresses the interest to protect both health care personnel and uninfected patients from unnecessary exposure (4) . While most of the management strategies discussed will be based on randomized controlled clinical trials (RCT), many of these are small and not necessarily generalizable to the current COVID-19 clinical environment. Therefore, some modifications are suggested to published approaches in places where the authors have experience. It bears emphasizing that it is generally not recommended that hospitals make major changes to their current approach to managing DKA as this may cause unintended consequences and result in the reverse outcome of requiring more ICU resources and time at the bedside.

In both the US and United Kingdom, DKA hospitalizations have risen sharply in the last decade, despite a decrease in the early part of this century.(5,6) Fortunately however, mortality from DKA has progressively declined over the last 3 decades and is most recently <0.5% in the US. Traditionally, mortality has been reported to be highest at the extremes of age, although mortality rates in the elderly have also declined dramatically during the past 10 years.(7) In type 1 diabetes (T1D), DKA is most often caused by missed insulin doses and death is rare with prompt treatment, while in type 2 diabetes (T2D), underlying severe illness is almost always the direct cause of both the DKA and ensuing death. Although DKA is more likely to occur in T1D, it is estimated that most DKA cases worldwide occur in T2D due to its higher prevalence. Probably as a result of increased diabetes screening and early recognition, DKA now occurs more frequently in persons with established diabetes rather than at the time of the initial diagnosis. (7) Since the year 2000, two new patient subtypes being hospitalized for DKA were identified. The first was the "ketosis-prone diabetes" population. Described in the early 2000s after an increase in DKA cases among persons with obesity and T2D was reported,(8) these patients had impaired insulin levels but lacked typical autoimmune markers of T1D, and their A c c e p t e d M a n u s c r i p t 8 beta-cell function recovered quickly after treatment. The other group is what the American Diabetes Association (ADA) has described as "euglycemic DKA" (euDKA), which makes up about 10% of patients with DKA. As seen in Case 1 presented above, euglycemic DKA is characterized by metabolic acidosis and increased total body ketone concentration, but with glucose levels ≤250 mg/dL.(9,10) EuDKA was first described in 1972, when Munro et al. A c c e p t e d M a n u s c r i p t 9

In the COVID-19 pandemic, it has been established that diabetes is a frequent comorbidity and is associated with increased severity of complications and mortality. (16) DKA has been reported in COVID-19 (17, 18) as with other severe infections (19) , in patients with both T1D and T2D. Following early studies from China reporting a wide prevalence of diabetes ranging between 7.4 and 19.5%, (20-22) several studies reported higher prevalence among those requiring hospitalization and/or those who died. Data from Italy, for example, reported that 35.5% of patients who died had diabetes, a prevalence greater than 3 times that of the general population. (23) In Chinese cohorts, ICU care was more often required for patients with diabetes (22.2% vs 5.9%, P=0.009), (21) and ARDS was 2.34 fold higher (95% CI, 3.6%-24.2%; P = .002). (24) As would be expected from the increased complications, mortality was also higher. One study from Wuhan of 191 patients showed an One likely important finding among COVID-19 patients is that severe disease is accompanied by high levels of inflammatory markers, which are also elevated in the setting of DKA independent of accompanying illness ( Figure 1 ).(2,25) IL-6 in particular has been highlighted as likely playing a role in a maladaptive immune response to the SARS-CoV-2 virus and has been proposed as a possible treatment target.(30) IL-6 has also been found to be elevated in DKA and is thought to be mostly a driver of ketosis rather than a result, but this is less clear. Historically and at present, the most common hospital setting utilized to administer DKA care has been the ICU. In the uncomplicated patient, this is largely due to the frequent glucose monitoring required in individuals receiving IVI where insulin adjustments are required frequently. In the case of DKA, ketosis, acidosis and elevated fatty acids all contribute to insulin resistance, (31, 33) as does hyperglycemia itself, (34) and as these resolve with simultaneous therapies (fluids and insulin), hypoglycemia risk is extremely high.

It is well established that the major pitfalls of DKA treatment include first inadequate potassium supplementation and second, failure to prevent hypoglycemia. (35) A close third on this list of pitfalls is the recurrence of ketoacidosis in the case of ineffective transitioning A c c e p t e d M a n u s c r i p t 12 of patients from IVI to subcutaneous insulin therapy. While there are numerous publications on how to avoid poor transitions, perhaps the most innovative and practical one tested the impact of administering long acting subcutaneous insulin, e.g. glargine, in the early phases of DKA treatment, and during IVI, in order to prevent rebound ketoacidosis and/or marked hyperglycemia. (36) As noted, DKA due to the use of SLGT2 inhibitors has led to DKA in the absence of marked hyperglycemia reported in hospitalized patients (13, 37) , while in practice it remains relatively uncommon. Interestingly, euDKA was rarely reported in SGLT2i clinical trials. (38) In a recent retrospective cohort study in Australia, those using SGLT2i had an odds ratio of 1.48 for DKA when compared with non-users, and 41% of these patients had a peak glucose <13.8 mmol/L (<250 mg/dL), compared with 0.8% of non-users.(39) Precipitating factors include acute illness with poor oral intake, vomiting, fasting, and reductions in insulin doses related to improved glycemic control (or missing doses during illness). While several potential mechanisms have been proposed, it is likely a combination of factors with volume depletion and decreased glucose availability at the tissue level playing key roles.

Management of euDKA includes the same triad approach as classical DKA, but with the clear distinction that dextrose containing fluids are required as an initial step rather than added later as glucose levels decline. The other key management point is that the glycosuria due to SGLT2i can persist for days, (40) and fluid resuscitation may need to be extended beyond the stage when the patient is taking normal oral fluid intake.

The ADA classifies the severity of DKA as mild, moderate or severe based on the extent of acidemia as measured by pH and/or bicarbonate deficit and alteration in patient's mental status. (Table 1 ). For all degrees of severity, the therapeutic triad is the same: fluid resuscitation, electrolyte repletion and insulin therapy. While simple in concept, each of these therapies have the potential to pose unique risks to patients depending on the degree of medical complexity identified upon presentation. For example, fluid resuscitation and A c c e p t e d M a n u s c r i p t 13 potassium repletion in the setting of severe AKI, and certainly ESRD, must be carefully considered. In these and other patients such as those with CHF or myocardial infarction, the risks and benefits of each therapy must be weighed often on an hourly basis and in an ICU setting. Due to the risk of hypoglycemia in critically ill patients, insulin treatment also requires frequent adjustment, thus forming the basis for IVI use in the ICU. Likewise, in severe COVID-19, the ICU is often needed for management including mechanical ventilation and vasopressor support and hence IVI is often the most appropriate mode of therapy when needed. As discussed below, the overall medical complexity of the patient ultimately determines the treatment strategy and the appropriate use of lower intensity therapies including subcutaneous insulin.

DKA management at home Patients experiencing hyperglycemia who are armed with ketone testing at home are better able to communicate with their care team on the severity of their illness when inpatient care is being considered. However, given the imprecision of point of care ketone testing, (41) any patient who has elevated ketones detected by any means should be assessed for other signs of possible DKA, e.g. nausea, vomiting and extreme thirst. In usual care, many patients who are clinically stable and can take oral fluids are able to self-manage early DKA with instructions and close communication with their care team. This has recently been described in COVID-19 patients by experienced diabetologists and in certain cases can prevent a hospitalization.(42) However, in most patients known to be COVID-19 positive, given the concern for rapid clinical decline, it is reasonable to recommend patients with a positive ketone test be evaluated urgently for detailed assessment including laboratory testing with a basic metabolic chemistry panel. Published studies of subcutaneous insulin use in DKA have used similar protocols but with important differences (see Table 2 ). All studies defined the patient population as uncomplicated mild or moderate DKA. Four of five trials included only adults and most subjects were reported as having poor compliance with diabetes therapy. In one study, patients were randomized to a regular IVI (0.1 unit/kg bolus followed by 0.1 units/kg/hr) vs.

an initial subcutaneous injection of 0.3 units/kg of lispro followed by 0.1 units/kg per hour until the glucose was <250 mg/dL. Although the subcutaneous insulin arm patients were managed on the general ward as compared with the ICU for the IVI group, both protocols required q1 hour glucose monitoring. The time required to achieve DKA resolution did not A c c e p t e d M a n u s c r i p t 15 differ between the groups. In a second study by the same group, the subcutaneous arm dosed subcutaneous aspart every 1 or every 2 hours and reported no difference in time to DKA resolution across groups [40. There was low-quality evidence to evaluate the effects of subcutaneous rapid-acting insulin analogues versus IVI on hypoglycemia, with both reporting no significant difference and overall low incidence with <10% of participants in both groups It is important to note that the subcutaneous insulin treatment modality has only been studied and recommended in uncomplicated patients with mild/moderate DKA as delineated above and in Table 1 . Subcutaneous strategies are not recommended for patients with severe DKA and/or other complicated illness (ESRD, severe AKI, pregnancy, concomitant MI or stroke, requiring ICU level of care for other reasons, e.g. mechanical ventilation and/or vasopressor support etc). For these patients, the critical care setting and use of IVI is required. Irrespective of the degree of acidosis and acidemia, patients with HHS or HK require close monitoring and therefore these patients require care in the ICU setting (10) A c c e p t e d M a n u s c r i p t 16

Severe DKA, in addition to other forms of hyperglycemic crisis, requires management in an ICU with access to IVI, frequent blood or capillary glucose monitoring (e.g. q1-2 hours), frequent laboratory monitoring (e.g. for potassium and electrolytes) and access to respiratory support and cardiac monitoring as needed. As noted previously, the resolution of DKA is heralded by a rapid increase in insulin sensitivity, which is more dramatic in severe DKA. This requires hourly adjustment of the insulin rate while dextrose-containing fluids are infused to avoid hypoglycemia. M a n u s c r i p t 17

The vast majority of people with diabetes who are infected with COVID-19 will not require hospitalization to manage their illness. Several authorities such as the CDC have advised against seeking care in the ED should individuals develop symptoms of COVID-19 but rather to contact their health care provider, seek testing in the community, and stay at home for mild to moderate symptoms using self care whenever possible.(45) For people with diabetes, self care includes continuing their home insulin and to reassess their oral therapies when necessary. Insulin deficient patients and those taking SGLT2 inhibitors should have ketone testing available to them at home should they develop illness. Many professional societies and patient advocacy groups have provided excellent resources for patients and providers alike to support a proactive approach to DKA prevention including reminding individuals with diabetes what to do when they become ill, e.g. "sick day rules." (46,47).

Additional key points specific to the pandemic include having all supplies on hand in the home in the event of illness or an emergency, e.g. hypoglycemia. This should include a 3 month supply of medications if affordable, all supplies needed for insulin therapy include insulin pump infusion sets or pods, in addition to a method to test ketone bodies (blood or urine) as discussed above.

People with T1D are likely at the highest risk of DKA during the pandemic independent of COVID-19 due to potential lapses in access to medicines or their care team.

As noted above, this decade has already seen a rise in DKA-related hospitalizations and hence additional attention has been paid to successful prevention programs. (48, 49) In the COVID-19 environment, services that may have reduced DKA risk may not be available to patients in the same form, especially early diabetes screening/identification and family-level education. Telemedicine is already a proven modality for DKA prevention in adolescents, and overall an effective tool to deliver diabetes care. (50, 51) During COVID-19 there is appropriate enthusiasm for enhanced telecommunication between adult patients and their A c c e p t e d M a n u s c r i p t 18 clinicians, including texting and frequent communication through EHR portals. To prevent provider burnout, this preventive "checking in" should be shared amongst the health care team members including nurses, pharmacists, dieticians and even administrative staff armed with standard communication tools. Finally, since DKA in type 1 is often caused by omission of insulin, and perhaps more commonly rationing insulin now, it is paramount for clinicians, clinical programs, hospital systems and insurers, as well as manufacturers come together to assist patients with diabetes to sustain their insulin regimes. Insulin manufacturers have recently established discount programs for those at highest risk in the US, e.g uninsured and

Medicare patients with high out-of-pocket requirements. (52) Patients taking SGLT2 inhibitors, as illustrated by this case, should be advised to discontinue the medication at the first sign of severe flu-like illness in order to prevent ketoacidosis.(13) As described above, COVID-19 infected patients taking these medications may be at a uniquely high risk for DKA. As it is not always possible to predict the course of COVID-19 and who will develop severe disease, the most practical advice for patients is discontinue the drug at the onset of any symptoms consistent with a viral syndrome.

Lastly, since at least 10% of patients worldwide present with DKA as the initial M a n u s c r i p t No difference in mean duration of treatment until resolution of hyperglycemia or ketoacidosis or rate of hypoglycemia between group Treatment in ICU was associated with 39% higher hospitalization charges than was treatment with subcutaneous lispro in a nonintensive care setting ($14,429 ± $5243 vs. $8801 ± $5549, P <0.01) Medical ward can be a safe environment for intensive subcut protocol though q1 hour monitoring used in all groups Abbreviations: IVI: Intravenous insulin; DM1: diabetes mellitus type 1; DM2: diabetes mellitus type 2, SC: subcutaneous; IV: intravenous; DKA: diabetic ketoacidosis; LOS: length of stay M a n u s c r i p t 

Adult hyperglycemic crisis: a review and perspective

Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises

Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State

Our Response to COVID-19 as Endocrinologists and Diabetologists

Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study

Increasing Hospitalizations for DKA: A Need for Prevention Programs

Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality -United States

Ketosis-prone type 2 diabetes: time to revise the classification of diabetes

Hyperglycemic crises in adult patients with diabetes

Euglycaemic diabetic ketoacidosis

Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes

Epidemiology of COVID-19 Among Children in China

Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations

Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus

Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports

DKA cases over the last three years: has anything changed?

Clinical Characteristics of 138 Hospitalized Patients With

China Medical Treatment Expert Group for C. Clinical Characteristics of Coronavirus Disease 2019 in China

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Mechanisms of Beta Cell Dysfunction Associated With Viral Infection

Hepatitis C virus infection and human pancreatic beta-cell dysfunction

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

COVID-19 infection may case ketosis and ketoacidosis

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management

Bicarbonate therapy in severe diabetic ketoacidosis. A double blind, randomized, placebo controlled trial

Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects

Glucose toxicity

Addressing Pitfalls in Management of Diabetic Ketoacidosis with a Standardized Protocol

Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia

Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors

Investigators E-RO. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission

Protracted glycosuria after discontinuation of sodium-glucose cotransporter 2 inhibitors: Implications for weekly dosing and extended risk of euglycemic diabetes ketoacidosis

Utility of ketone measurement in the prevention, diagnosis and management of diabetic ketoacidosis. Diabetic medicine : a journal of the

The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth

Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis

A Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic

ISPAD Clinical Practice Consensus Guidelines 2018: Sick day management in children and adolescents with diabetes

Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up

Finnish Diabetes Registry Study G. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up

NICH at Its Best for Diabetes at Its Worst: Texting Teens and Their Caregivers for Better Outcomes

Telemedicine in Complex Diabetes Management

Preventing Diabetic Ketoacidosis

Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis

A c c e p t e d M a n u s c r i p t 25 A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 27 A c c e p t e d M a n u s c r i p t 28

Ersoz A c c e p t e d M a n u s c r i p t 29 Figure 1